EISAI

Clarity AD

Lecanemab antibody targets amyloid-beta plaques in the brain to potentially slow the progression of Alzheimer’s disease. This study examines its impact on cognitive function over 18 months, with an extension phase to monitor long-term safety and effects.

Status: ACTIVE, NOT RECRUITING

FDA Approved

Application











    All information provided is confidential and will not be given or sold to any other agency without prior consent.